

This document constitutes a supplement (the "**Supplement**") within the meaning of Article 23 (1) of Regulation (EU) 2017/1129 of the European Parliament and the Council of 14 June 2017, as amended (the "**Prospectus Regulation**") to two base prospectuses of Deutsche Apotheker- und Ärztebank eG (the "**Issuer**"): (i) the base prospectus in respect of non-equity securities and (ii) the base prospectus in respect of Pfandbriefe (together, the "**Debt Issuance Programme Prospectus**" or the "**Prospectus**").

This Supplement is supplemental to and should be read in conjunction with the Prospectus.

Supplement No.1 dated 2 July 2021
to the Debt Issuance Programme Prospectus dated 11 May 2021



Deutsche Apotheker- und Ärztebank eG
Düsseldorf, Federal Republic of Germany

as Issuer

€ 15,000,000,000

Debt Issuance Programme (the "Programme")

The Issuer has requested the *Commission de Surveillance du Secteur Financier* of the Grand Duchy of Luxembourg (the "**CSSF**") in its capacity as competent authority under the Prospectus Regulation and the Law of 16 July 2019 on Prospectuses for Securities (*Loi du 16 juillet 2019 relative aux prospectus pour valeurs mobilières*) (the "**Luxembourg Law**") to approve this Supplement and to provide the competent authorities in the Federal Republic of Germany and the Republic of Austria with a certificate of approval attesting that this Supplement has been drawn up in accordance with the Prospectus Regulation (each a "**Notification**"). The Issuer may request the CSSF to provide competent authorities in additional host Member States within the European Economic Area with a Notification.

This Supplement has been approved by the CSSF, has been filed with said authority and will be published in electronic form on the website of the Luxembourg Stock Exchange (www.bourse.lu) and on the website of the Issuer (www.apobank.de).

RESPONSIBILITY STATEMENT

Deutsche Apotheker- und Ärztebank eG ("**apoBank**", the "**Bank**" or the "**Issuer**") is solely responsible for the information given in this Supplement. The Issuer hereby declares that, to the best of its knowledge, the information contained in this Supplement is in accordance with the facts and that this Supplement makes no omission likely to affect its import.

Terms defined or otherwise attributed meanings in the Prospectus have the same meaning when used in this Supplement.

This Supplement shall only be distributed in connection with the Prospectus. It should only be read in conjunction with the Prospectus. Full information on the Issuer and any Tranche (as defined in the Prospectus) of notes (the "Notes", which expression includes Pfandbriefe unless otherwise indicated) is only available on the basis of the combination of this Supplement, the Prospectus and the relevant Final Terms.

To the extent that there is any inconsistency between any statement in this Supplement and any other statement in or incorporated by reference in the Prospectus, the statements in this Supplement will prevail.

Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus which may affect the assessment of the Notes to be issued under this Programme since the publication of the Prospectus.

The Issuer has confirmed to the Dealers that the Prospectus and this Supplement contain all information with regard to the Issuer and the Notes which is material in the context of the Programme and the issue and offering of Notes thereunder; that the information contained therein with respect to the Issuer and the Notes is accurate in all material respects and is not misleading; that any opinions and intentions expressed therein with respect to the Issuer and the Notes are honestly held; that there are no other facts with respect to the Issuer or the Notes the omission of which would make the Prospectus and this Supplement as a whole or any of such information or the expression of any such opinions or intentions misleading and that the Issuer has made all reasonable enquiries to ascertain all facts material for the purposes aforesaid.

No person has been authorised to give any information which is not contained in or not consistent with the Prospectus as supplemented by this Supplement or any other document entered into or any other information supplied by the Issuer in connection with the Programme and, if given or made, such information must not be relied upon as having been authorised by the Issuer, the Dealers or any of them.

Neither the Arranger nor any of the Dealers, any financial intermediaries or any other person mentioned in the Prospectus as supplemented by this Supplement, excluding the Issuer, is responsible for the information contained in the Prospectus as supplemented by this Supplement or any Final Terms or any other document incorporated therein by reference, and, accordingly and to the extent permitted by the laws of any relevant jurisdiction, none of these persons accepts any responsibility for the accuracy or completeness of the information contained in any of these documents.

The Prospectus as supplemented by this Supplement as well as any Final Terms reflect the status as at their respective dates of issue. The delivery of the Prospectus as supplemented by this Supplement and any Final Terms and the offering, sale or delivery of any Notes may not be taken as an implication that the information contained in such documents is accurate and complete subsequent to their respective dates of issue or that there has been no adverse change in the financial situation of the Issuer since such date or that any other information supplied in connection with the Programme is accurate at any time subsequent to the date on which it is supplied or, if different, the date indicated in the document containing the same.

RIGHT TO WITHDRAW

In accordance with Article 23 (2a) of the Prospectus Regulation, where the Prospectus as supplemented by this Supplement relates to an offer of Notes to the public, investors who had already agreed to purchase or subscribe for the Notes before this Supplement was published and where the Notes had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted have the right, exercisable within three working days after the publication of this Supplement, beginning on 5 July 2021 and ending on 7 July 2021, to withdraw their acceptances. Investors wishing to exercise the right of withdrawal may contact the Issuer under the address specified at the end of this Supplement. The final date of the right of withdrawal will be 7 July 2021.

CAUSAL FACTOR FOR THE SUPPLEMENT

The significant new factor on the basis of which this Supplement has been prepared is the publication by S&P Global Ratings Europe Limited (Germany branch) as of 24 June 2021 regarding the changes to the issuer rating of apoBank from AA- to A+ and the short-term rating from A-1+ to A-1 (the "**causal factor for the Supplement**"). The causal factor for the Supplement, therefore, took effect on 24 June 2021.

**Replacement information pertaining to the section "DEUTSCHE APOTHEKER- UND
ÄRZTEBANK EG"**

The paragraphs under the heading "INFORMATION ABOUT APOBANK – Issuer Credit Ratings" on pages 28 and 29 of the Prospectus shall be replaced by the following:

"apoBank is rated by S&P Global Ratings Europe Limited ("**S&P**")¹. The ratings assigned to apoBank by S&P are as follows²:

Long-term rating: A+

Short-term rating: A-1;

Definitions:

A: An obligor rated 'A' has strong capacity to meet its financial commitments but is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than obligors in higher-rated categories.

Note:

Ratings from 'AA' to 'CCC' may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the rating categories.

A-1: An obligor rated 'A-1' has strong capacity to meet its financial commitments. It is rated in the highest category by S&P. Within this category, certain obligors are designated with a plus sign (+). This indicates that the obligor's capacity to meet its financial commitments is extremely strong."

¹ S&P is established in the European Community and registered since 31 October 2011 under Regulation (EC) No 1060/2009 of the European Parliament and of the Council of 16 September 2009 on credit rating agencies, as amended, (the "**CRA Regulation**"). S&P is included in the "List of registered and certified CRA's" published by the European Securities and Markets Authority on its website (www.esma.europa.eu) in accordance with the CRA Regulation.

² The current ratings may be obtained from apoBank's website: www.apobank.de. A rating is not a recommendation to buy, sell or hold Notes issued under this Programme and may be subject to suspension, reduction or withdrawal at any time by the assigning rating agency. A suspension, reduction or withdrawal of the rating assigned to apoBank may adversely affect the market price of the Notes issued under this Programme.

NAMES AND ADDRESSES

Issuer

Deutsche Apotheker- und Ärztebank eG
Richard-Oskar-Mattern-Straße 6
40547 Düsseldorf
Germany

Fiscal Agents

Deutsche Bank Aktiengesellschaft
Taunusanlage 12
60325 Frankfurt am Main
Germany

Deutsche Apotheker- und Ärztebank eG
Richard-Oskar-Mattern-Straße 6
40547 Düsseldorf
Germany

Listing Agent in Luxembourg

Banque de Luxembourg
14, Boulevard Royal
2449 Luxembourg
Luxembourg